Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
NEOPA
2012-003669-17Phase 3Terminated
- Sponsor
- University Medical Center Hamburg-Eppendorf
- Start
- Apr 2013
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, open-label trial of gemcitabine in pancreatic adenocarcinoma (PDAC) (2 arms), sponsored by University Medical Center Hamburg-Eppendorf. Primary endpoint: Survival time. Started Apr 2013; status: terminated.
02
Drugs
gemcitabine
03
Conditions
pancreatic adenocarcinoma (PDAC)
Beyond the preview
Go deeper on 2012-003669-17.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2012-003669-17.